Rôle de la MGMT et implications cliniques dans les tumeurs cérébrales [Role of MGMT and clinical applications in brain tumours]

Details

Serval ID
serval:BIB_72D7781ECE93
Type
Article: article from journal or magazin.
Publication sub-type
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Collection
Publications
Institution
Title
Rôle de la MGMT et implications cliniques dans les tumeurs cérébrales [Role of MGMT and clinical applications in brain tumours]
Journal
Bulletin du cancer
Author(s)
Paus C., Murat A., Stupp R., Regli L., Hegi M.
ISSN
1769-6917[electronic]
Publication state
Published
Issued date
2007
Volume
94
Number
9
Pages
769-73
Language
french
Notes
Publication types: English Abstract ; Journal Article ; Review - Publication Status: ppublish
Abstract
Glioblastoma multiforme is the most common and most malignant primary brain tumour with a dismal prognosis. The advent of new chemotherapies with alkylating agents crossing the blood-brain barrier, like temozolomide, have permitted to notably ameliorate the survival of a subgroup of patients. Improved outcome was associated with epigenetic silencing of the MGMT (O6-methylguanin methyltransferase) gene by promotor methylation, thereby blocking its repair capability, thus rendering the alkylating agents more effective. This particularity can be tested by methylation specific PCR on resected tumour tissue, best on fresh frozen biopsies, and allows identification of patients more susceptible to respond favourably to the treatment.
Keywords
Antineoplastic Agents, Alkylating, Brain Neoplasms, DNA Methylation, DNA Modification Methylases, DNA Repair Enzymes, Drug Resistance, Neoplasm, Gene Silencing, Gene Targeting, Glioblastoma, Humans, Neoplasm Proteins, Promoter Regions, Genetic, Treatment Outcome, Tumor Suppressor Proteins
Pubmed
Web of science
Create date
30/07/2008 9:39
Last modification date
20/08/2019 14:30
Usage data